Contents

Search

sofosbuvir/velpatasvir/voxilaprevir (Vosevi)

Indications: - treatment of hepatitis C genotypes 1-6 without cirrhosis (FDA-approved July 2017)

Interactions

drug interactions

General

pharmacologic combination

References

  1. FDA News Release. July 18, 2017 FDA approves Vosevi for Hepatitis C https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm - Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871 - U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  2. Bourliere M, Gordon SC, Flamm SL et al Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 Jun 1;376(22):2134-2146. PMID: 28564569 Free Article

Components

sofosbuvir (Sovaldi) velpatasvir voxilaprevir